Coexistence of chronic lymphocytic leukaemia and polycythemia vera

Keywords: Chronic Lymphocytic Leukaemia, Polycythemia Vera, JAK2 V617F mutation, germline mutations

Abstract


We report a rare case of coexistence of chronic lymphocytic leukaemia (CLL) and polycythemia vera (PV) in a patient initially diagnosed and treated for CLL. A 61-year-old man presented with fatigue and night sweats, with laboratory tests showing elevated haemoglobin, hematocrit (HCT), leukocyte count and splenomegaly. Peripheral blood smear revealed lymphocytosis with basket cells, and flow cytometry confirmed CLL (RAI stage II). FISH analysis was negative for del13q, del11q, trisomy 12, del 17p and del6q. Chemotherapy was started because of B symptoms. Persistent splenomegaly and elevated HCT at follow-up prompted further evaluation, which revealed a JAK2 V617F mutation and an erythropoietin (EPO) level <1 mIU/mL, confirming PV. The patient achieved remission for CLL, but required hydroxyurea and acetylsalicylic acid for PV. The coexistence of CLL and PV is rare and the underlying mechanisms are not well understood, although a common clonal haematopoietic stem cell origin or germline mutations are possible explanations. Although chemotherapeutic agents are known to induce PV, the elevated HCT at the time of CLL diagnosis suggests a pre-existing relationship between the two diseases. Therefore, elevated HCT in CLL patients should prompt consideration of PV.

References

Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management. American J Hematol. 2023;98(9):1465-1487. doi:10.1002/ajh.27002.

Rumi E, Passamonti F, Elena C, Pietra D, Arcaini L, Astori C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica. 2011;96:454-8. doi: 10.3324/haematol.2010.033779.

Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica. 2011;96:450-53. doi:10.3324/haematol.2010.033191.

Lenartova A, Johannesen TB, Tjønnfjord GE. Chronic lymphocytic leukemia and secondary hematological malignancies: A nation‐wide cancer registry study. European J of Haematology. 2020;104:546-53. doi:10.1111/ejh.13396.

Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB, et al. JAK2(V617F): Prevalence in a large Chinese hospital population. Blood. 2007 1;109:339-42. doi: 10.1182/blood-2006-03-009472.

Stijnis C, Kroes WG, Balkassmi S, Marijt EW, van Rossum AP, et al. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder. Acta Haematol. 2012;128:183-6. doi: 10.1159/000338831.

Lim TL, Lieberman DB, Davis AR, Loren AW, Hausler R, Bigdeli A, et al. Germline POT1 variants can predispose to myeloid and lymphoid neoplasms. Leukemia. 2022;36:283-87. doi: 10.1038/s41375-021-01335-w.

Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F,et al. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol. 2011;86:1007-12. doi: 10.1002/ajh.22171.

Bucelli C, Fattizzo B, Cattaneo D, Giannotta JA, Barbullushi K, Pasquale R, et al. Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study. Front Oncol. 2021;18;11:701604. doi: 10.3389/fonc.2021.701604.

Zielinska P, Markiewicz M, Dzierzak-Mietla M, Koclega A, Helbig G, Kyrcz-Krzemien S. Coexistence of Chronic Lymphocytic Leukemia and Myeloproliferative Neoplasm. Case Reports in Oncological Medicine. 2014;2014:1-4. doi:10.1155/2014/512928.

Published
2025/10/23
Section
Case report